Sharps Technology Inc. (STSS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
0.47
-0.99 (-67.81%)
At close: Jan 28, 2025, 2:11 PM
Company Description
Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States.
It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications.
The company was incorporated in 2017 and is based in Melville, New York.
Sharps Technology Inc.
Country | United States |
IPO Date | Apr 14, 2022 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 57 |
CEO | Robert M. Hayes |
Contact Details
Address: 105 Maxess Road Melville, New York United States | |
Website | https://sharpstechnology.com |
Stock Details
Ticker Symbol | STSS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001737995 |
CUSIP Number | 82003F101 |
ISIN Number | US82003F1012 |
Employer ID | 82-3751728 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Robert M. Hayes | Chief Executive Officer & Director |
Ben Scheu | Senior Director of Sales |
Dr. Steven Hertz M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 27, 2025 | S-1/A | [Amend] Filing |
Jan 27, 2025 | S-1/A | [Amend] Filing |
Jan 22, 2025 | S-1/A | [Amend] Filing |
Jan 22, 2025 | 8-K | Current Report |
Jan 10, 2025 | S-1 | Filing |
Dec 23, 2024 | 8-K | Current Report |
Dec 23, 2024 | S-3 | Filing |
Dec 09, 2024 | 253G3 | Filing |
Dec 06, 2024 | 4/A | [Amend] Filing |
Dec 06, 2024 | 8-K | Current Report |